title: Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.
abstract: Inhibition of renin with an active site inhibitor, aliskiren, lowers blood pressure (BP) in diabetic patients. Here, we studied the time course of the antihypertensive and antiproteinuric effect of renin inhibition in 15 patients with type 2 diabetes and elevated urinary albumin/creatinine ratios (UACRs) to check whether aliskiren can decrease proteinuria. After a 4-week washout of previous medications, patients received aliskiren and furosemide daily for 28 days followed by a 4-week withdrawal period. Twenty-four-hour BPs were measured at baseline throughout treatment and withdrawal periods. The UACR was significantly reduced after 2-4 days of treatment with another significant reduction after 28 days. Systolic blood pressure (SBP) was significantly lower after 7 days with no further reduction after 28 days. The BP returned toward baseline 3 days after withdrawal, whereas the UACR was still significantly reduced compared with baseline 12 days after withdrawal. Our study shows that aliskiren reduced 24 h SBP, and this was associated with a reduction in albuminuria in type 2 diabetic patients.
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark. frip@steno.dk
authors.forename: F
authors.initials: F
authors.lastname: Persson
authors.forename: P
authors.initials: P
authors.lastname: Rossing
authors.forename: K J
authors.initials: KJ
authors.lastname: Schjoedt
authors.forename: T
authors.initials: T
authors.lastname: Juhl
authors.forename: L
authors.initials: L
authors.lastname: Tarnow
authors.forename: C D A
authors.initials: CD
authors.lastname: Stehouwer
authors.forename: C
authors.initials: C
authors.lastname: Schalkwijk
authors.forename: F
authors.initials: F
authors.lastname: Boomsma
authors.forename: E
authors.initials: E
authors.lastname: Frandsen
authors.forename: H-H
authors.initials: HH
authors.lastname: Parving
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D000577:Amides / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D005650:Fumarates / Q000494:pharmacology / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D003404:Creatinine; D005650:Fumarates; D000092502:Renin Inhibitors; C446481:aliskiren